Thursday, December 15, 2011 3:48:57 PM
December 15, 2011
07:56 EDT AIS, BPAX
theflyonthewall.com: Antares decline on LibiGel data overdone, says Oppenheimer
After Antares' (AIS) partner, BioSante (BPAX), announced disappointing efficacy data for female sexual dysfunction treatment LibiGel, Oppenheimer thinks that the placebo effect shown in the trial will be difficult to overcome. The firm lowered its target on Antares to $3 from $3.20 but maintains an Outperform rating. :theflyonthewall.com
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM